A 2026 Frontiers paper (European perspective) is highly relevant to pharma quality teams because it focuses on LLMs for process automation and compliance work (SOP automation, audit documentation, deviation management, compliance monitoring) and explicitly discusses the EU regulatory context (MDR/GDPR/EU AI Act). It also highlights the evaluation gap (lots of “accuracy-only” studies; little real-world deployment evidence) and argues for validation approaches that acknowledge non-determinism.
Wednesday, June 10, 2026
Open-access paper: LLMs in quality management with a risk-stratified deployment model (Frontiers, 2026)
EMA explains how its AI tool “Scientific Explorer” is validated and controlled (FAQ updated March 2026)
EMA published a short FAQ describing “Scientific Explorer,” an AI-enabled search tool used by the EU regulatory network to find regulatory precedents. The pharma-relevant part is the transparency: EMA describes it as information retrieval, not “AI generating new decisions,” and gives concrete validation metrics (F1 score range) plus hosting/governance details (secure EU cloud; no training new models on EMA data).
EMA/HMA published the 2025 AI Observatory Report (June 2026)
EMA and the Heads of Medicines Agencies released their annual “AI Observatory” report, which is effectively a regulatory horizon scan of where AI is already showing up in submissions, regulator operations, and EU-funded regulatory science. A key value of this report is that it doesn’t just talk about AI—it documents where regulators see real activity and where the gaps remain (notably: “regulatory-grade” model validation and auditability).